CatSci to Attend DCAT 2024

CatSci Ltd, an award-winning innovation partner for medicines development, are pleased to share that we will be attending DCAT Week, New York City, on 18^th – 21^st March 2024. Hosted by the Drug, Chemical & Associated Technologies Association, DCAT Week is a global annual event for the bio/pharmaceutical manufacturing chain. 

Attending DCAT will be:

• Dr Simon Tyler, Chief Commercial Officer
• Autumn Collins, Business Development Manager – East Coast

Simon and Autumn are looking forward to networking with the industry and exploring how CatSci can address your CMC challenges. Our in-depth drug development capabilities span from preclinical through all phases of development, commercialisation and post approval changes across chemistry, GMP-analytical, HPAPIs, material sciences and preformulation. We also have a dedicated start-of-the-art oligonucleotide facilities, which enables the synthesis of all classes of therapeutic oligos, including siRNA, ASO, Gapmers and sgRNA, as well as GalNAc ligands and other conjugates at up to a 30g scale. 

From candidate selection through product launch and beyond, CatSci can de-risk your pharmaceutical pipeline and accelerate your path to clinic. We are your trusted innovation partner for medicines development, and the CatSci team are looking forward to networking with the community and discussing how we can meet your dynamic portfolio demands. 

To book a meeting with us at DCAT, get in touch here.